{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:38:43Z","timestamp":1788385123564,"version":"build-2803163510"},"reference-count":71,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background: Large B-cell lymphomas (LBCLs) form a notable subgroup of lymphomas; however, their associated long-term comorbidities and mortality rates remain under-researched in real-world settings.\nMaterial and methods: This nationwide Finnish population-based matched cohort study included virtually all LBCL patients (N = 7,019) diagnosed from 2008 to 2019, alongside age, sex, and region-matched controls (1:1 ratio) without lymphoma. Diagnoses of LBCLs were obtained from the Finnish Cancer Registry, with data linked to additional nationwide registries. Baseline characteristics were summarised using descriptive statistics. Overall survival (OS) was estimated using the Kaplan-Meier method, while Cox regression was used to analyse factors associated with OS and evaluate the risk and associated factors of comorbidities considering the competing risk of death.\nResults: The 5-year survival rate for LBCL patients, median age 70.7 years and 52.7% male, was 50.0% (95% Confidence Interval [CI] 48.7% \u2013 51.3%), compared to 82.6% (95% CI 81.5% \u2013 83.6%) for controls. Among LBCL patients, older age and a higher Charlson comorbidity index were associated with increased mortality. Conversely, female sex, later diagnosis year, and radiation therapy were associated with improved survival. Patients with LBCL exhibited an elevated risk of long-term comorbidities, including solid tumours, hematological and skin cancers, lung and thyroid diseases, mental and behavioral disorders, and cardiovascular diseases. After 12 years of follow-up, lymphoma accounted for the primary cause of death in approximately 43% of LBCL patients.\nInterpretation: Large B-cell lymphomas are linked with significant long-term comorbidities and elevated mortality rates.<\/jats:p>","DOI":"10.2340\/1651-226x.2025.42539","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T07:34:25Z","timestamp":1740468865000},"page":"303-311","source":"Crossref","is-referenced-by-count":3,"title":["Population based registry study on large B-cell lymphoma mortality and morbidity in Finland"],"prefix":"10.2340","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4041-8044","authenticated-orcid":false,"given":"Anna","family":"Anttalainen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0770-361X","authenticated-orcid":false,"given":"Liisa","family":"Ukkola-Vuoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ville","family":"Vihervaara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saija","family":"Silvola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9969-0053","authenticated-orcid":false,"given":"Outi","family":"Kuittinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"100535","doi-asserted-by":"crossref","unstructured":"Susanibar\u2010Adaniya S, Barta SK. 2021 Update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management. Am J Hematol. 2021;96:617\u201329.","DOI":"10.1002\/ajh.26151"},{"key":"100536","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/ajh.26151","DOI":"10.1002\/ajh.26151"},{"key":"100537","doi-asserted-by":"crossref","unstructured":"Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50:74\u201387.","DOI":"10.1016\/j.pathol.2017.09.006"},{"key":"100538","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.pathol.2017.09.006","DOI":"10.1016\/j.pathol.2017.09.006"},{"key":"100539","doi-asserted-by":"crossref","unstructured":"Nastoupil LJ, Bartlett NL. Navigating the evolving treatment landscape of diffuse large B-cell lymphoma. JCO. 2023;41:903\u201313.","DOI":"10.1200\/JCO.22.01848"},{"key":"100540","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.22.01848","DOI":"10.1200\/JCO.22.01848"},{"key":"100541","doi-asserted-by":"crossref","unstructured":"Ekberg S, Jerkeman M, Andersson P, Enblad G, Wahlin BE, Hasselblom S, et al. Long\u2010term survival and loss in expectancy of life in a popu-lation\u2010based cohort of 7114 patients with diffuse large B\u2010cell lymphoma. Am J Hematol. 2018;93:1020\u20138.","DOI":"10.1002\/ajh.25147"},{"key":"100542","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/ajh.25147","DOI":"10.1002\/ajh.25147"},{"key":"100543","doi-asserted-by":"crossref","unstructured":"Coiffier B, Lepage E, Bri\u00e8re J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235\u201342.","DOI":"10.1056\/NEJMoa011795"},{"key":"100544","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa011795","DOI":"10.1056\/NEJMoa011795"},{"key":"100545","doi-asserted-by":"crossref","unstructured":"Maurer MJ, Ghesqui\u00e8res H, Jais J-P, Witzig TE, Haioun C, Thompson CA, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. JCO. 2014;32:1066\u201373.","DOI":"10.1200\/JCO.2013.51.5866"},{"key":"100546","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.2013.51.5866","DOI":"10.1200\/JCO.2013.51.5866"},{"key":"100547","doi-asserted-by":"crossref","unstructured":"Abu Sabaa A, M\u00f6rth C, Hasselblom S, Hedstr\u00f6m G, Flogeg\u00e5rd M, Stern M, et al. Age is the most important predictor of survival in diffuse large B\u2010cell lymphoma patients achieving event\u2010free survival at 24 months: a Swedish population\u2010based study. Br J Haematol. 2021;193:906\u201314.","DOI":"10.1111\/bjh.17206"},{"key":"100548","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjh.17206","DOI":"10.1111\/bjh.17206"},{"key":"100549","doi-asserted-by":"crossref","unstructured":"Howlader N, Mariotto AB, Besson C, Suneja G, Robien K, Younes N, et al. Cancer\u2010specific mortality, cure fraction, and noncancer causes of death among diffuse large B\u2010cell lymphoma patients in the immunochemotherapy era. Cancer. 2017;123:3326\u201334.","DOI":"10.1002\/cncr.30739"},{"key":"100550","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/cncr.30739","DOI":"10.1002\/cncr.30739"},{"key":"100551","doi-asserted-by":"crossref","unstructured":"Jakobsen LH, B\u00f8gsted M, Brown PDN, Arboe B, J\u00f8rgensen J, Larsen TS, et al. Minimal loss of lifetime for patients with diffuse large B-cell lymphoma in remission and event free 24 months after treatment: a Danish population-based study. JCO. 2017;35:778\u201384.","DOI":"10.1200\/JCO.2016.70.0765"},{"key":"100552","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.2016.70.0765","DOI":"10.1200\/JCO.2016.70.0765"},{"key":"100553","doi-asserted-by":"crossref","unstructured":"Witkowska M, Majchrzak A, Smolewski P. The role of radiotherapy in Hodgkin\u2019s lymphoma: what has been achieved during the last 50 years? BioMed Res Int. 2015;2015:1\u20138.","DOI":"10.1155\/2015\/485071"},{"key":"100554","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1155\/2015\/485071","DOI":"10.1155\/2015\/485071"},{"key":"100555","doi-asserted-by":"crossref","unstructured":"Harkins RA, Patel SP, Flowers CR. Cost burden of diffuse large B-cell lymphoma. Expert Rev Pharmacoecon Outcomes Res. 2019;19:645\u201361.","DOI":"10.1080\/14737167.2019.1680288"},{"key":"100556","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/14737167.2019.1680288","DOI":"10.1080\/14737167.2019.1680288"},{"key":"100557","doi-asserted-by":"crossref","unstructured":"Wang H-I, Smith A, Aas E, Roman E, Crouch S, Burton C, et al. Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort. Eur J Health Econ. 2017;18:255\u201367.","DOI":"10.1007\/s10198-016-0775-4"},{"key":"100558","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s10198-016-0775-4","DOI":"10.1007\/s10198-016-0775-4"},{"key":"100559","doi-asserted-by":"crossref","unstructured":"Sund R. Quality of the Finnish Hospital Discharge Register: a systematic review. Scand J Public Health. 2012;40:505\u201315.","DOI":"10.1177\/1403494812456637"},{"key":"100560","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/1403494812456637","DOI":"10.1177\/1403494812456637"},{"key":"100561","doi-asserted-by":"crossref","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173:676\u201382.","DOI":"10.1093\/aje\/kwq433"},{"key":"100562","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/aje\/kwq433","DOI":"10.1093\/aje\/kwq433"},{"key":"100563","doi-asserted-by":"crossref","unstructured":"Wang J, Zhou M, Zhou R, Xu J, Chen B. Nomogram for predicting the overall survival of adult patients with primary gastrointestinal diffuse large B cell lymphoma: a SEER- based study. Front Oncol. 2020;10:1093.","DOI":"10.3389\/fonc.2020.01093"},{"key":"100564","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fonc.2020.01093","DOI":"10.3389\/fonc.2020.01093"},{"key":"100565","doi-asserted-by":"crossref","unstructured":"Tuominen S, Uusi-Rauva K, Blom T, Jyrkki\u00f6 S, Tuppurainen K, Alanne E. Real-world data on diffuse large B-cell lymphoma in 2010\u20132019: usability of large data sets of Finnish hospital data lakes. Future Oncol. 2022;18:1103\u201314.","DOI":"10.2217\/fon-2021-0806"},{"key":"100566","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2217\/fon-2021-0806","DOI":"10.2217\/fon-2021-0806"},{"key":"100567","doi-asserted-by":"crossref","unstructured":"Puhakka I, Kuitunen H, J\u00e4k\u00e4l\u00e4 P, Sonkaj\u00e4rvi E, Turpeenniemi-Hujanen T, R\u00f6nk\u00e4 A, et al. Primary central nervous system lymphoma high incidence and poor survival in Finnish population-based analysis. BMC Cancer. 2022;22:236.","DOI":"10.1186\/s12885-022-09315-8"},{"key":"100568","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s12885-022-09315-8","DOI":"10.1186\/s12885-022-09315-8"},{"key":"100569","doi-asserted-by":"crossref","unstructured":"Vaughn JL, Epperla N. Survival of patients with transformed follicular lymphoma in the United States: a multiple cohort study. Biomark Res. 2023;11:84.","DOI":"10.1186\/s40364-023-00525-1"},{"key":"100570","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s40364-023-00525-1","DOI":"10.1186\/s40364-023-00525-1"},{"key":"100571","doi-asserted-by":"crossref","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBDO, Berti E, et al. The 5th edition of the World Health Organization classifi-cation of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720\u201348.","DOI":"10.1038\/s41375-022-01620-2"},{"key":"100572","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41375-022-01620-2","DOI":"10.1038\/s41375-022-01620-2"},{"key":"100573","doi-asserted-by":"crossref","unstructured":"Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. The World Health Organization classification of hemato-logical malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol. 2000;13:193\u2013207.","DOI":"10.1038\/modpathol.3880035"},{"key":"100574","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/modpathol.3880035","DOI":"10.1038\/modpathol.3880035"},{"key":"100575","doi-asserted-by":"crossref","unstructured":"Ermann DA, Vardell VA, Shah H, Fitzgerald L, Tao R, Gaffney DK, et al. Survival outcomes of limited-stage diffuse large B-cell lymphoma treated with radiation therapy. Clin Lymphoma Myeloma and Leuk. 2024;24:94\u2013104.e6.","DOI":"10.1016\/j.clml.2023.09.006"},{"key":"100576","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.clml.2023.09.006","DOI":"10.1016\/j.clml.2023.09.006"},{"key":"100577","doi-asserted-by":"crossref","unstructured":"Glimelius I, Ekberg S, Ekstr\u00f6m Smedby K, W\u00e4sterlid T. Stable use of radiotherapy in lymphoma patients over time \u2013 a comprehensive national overview of radiotherapy use in Sweden with focus on older patients. Clin Transl Radiat Oncol. 2024;46:100785.","DOI":"10.1016\/j.ctro.2024.100785"},{"key":"100578","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ctro.2024.100785","DOI":"10.1016\/j.ctro.2024.100785"},{"key":"100579","doi-asserted-by":"crossref","unstructured":"Tokola S, Kuitunen H, Turpeenniemi\u2010Hujanen T, Kuittinen O. Significance of bulky mass and residual tumor \u2013 treated with or without con-solidative radiotherapy \u2013 to the risk of relapse in DLBCL patients. Cancer Med. 2020;9:1966\u201377.","DOI":"10.1002\/cam4.2798"},{"key":"100580","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/cam4.2798","DOI":"10.1002\/cam4.2798"},{"key":"100581","doi-asserted-by":"crossref","unstructured":"Cook MB, McGlynn KA, Devesa SS, Freedman ND, Anderson WF. Sex disparities in cancer mortality and survival. Cancer Epidemiol Bi-omarkers Prev. 2011;20:1629\u201337.","DOI":"10.1158\/1055-9965.EPI-11-0246"},{"key":"100582","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1158\/1055-9965.EPI-11-0246","DOI":"10.1158\/1055-9965.EPI-11-0246"},{"key":"100583","doi-asserted-by":"crossref","unstructured":"Radkiewicz C, Bruchfeld JB, Weibull CE, Jeppesen ML, Frederiksen H, Lambe M, et al. Sex differences in lymphoma incidence and mortality by subtype: a population\u2010based study. Am J Hematol. 2023;98:23\u201330.","DOI":"10.1002\/ajh.26744"},{"key":"100584","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/ajh.26744","DOI":"10.1002\/ajh.26744"},{"key":"100585","doi-asserted-by":"crossref","unstructured":"Durmaz M, Visser O, Posthuma EFM, Brouwer RE, Issa DE, De Jong D, et al. Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989\u20132018. Blood Cancer J. 2022;12:38.","DOI":"10.1038\/s41408-022-00637-1"},{"key":"100586","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41408-022-00637-1","DOI":"10.1038\/s41408-022-00637-1"},{"key":"100587","doi-asserted-by":"crossref","unstructured":"Rock CB, Chipman JJ, Parsons MW, Weil CR, Hutten RJ, Tao R, et al. Second primary malignancies in diffuse large B-cell lymphoma survivors with 40 years of follow up: influence of chemotherapy and radiation therapy. Adv Radiat Oncol. 2022;7:101035.","DOI":"10.1016\/j.adro.2022.101035"},{"key":"100588","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.adro.2022.101035","DOI":"10.1016\/j.adro.2022.101035"},{"key":"100589","doi-asserted-by":"crossref","unstructured":"Tao L, Clarke CA, Rosenberg AS, Advani RH, Jonas BA, Flowers CR, et al. Subsequent primary malignancies after diffuse large B\u2010cell lym-phoma in the modern treatment era. Br J Haematol. 2017;178:72\u201380.","DOI":"10.1111\/bjh.14638"},{"key":"100590","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjh.14638","DOI":"10.1111\/bjh.14638"},{"key":"100591","doi-asserted-by":"crossref","unstructured":"Major A, Smith DE, Ghosh D, Rabinovitch R, Kamdar M. Risk and subtypes of secondary primary malignancies in diffuse large B\u2010cell lym-phoma survivors change over time based on stage at diagnosis. Cancer. 2020;126:189\u2013201.","DOI":"10.1002\/cncr.32513"},{"key":"100592","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/cncr.32513","DOI":"10.1002\/cncr.32513"},{"key":"100593","doi-asserted-by":"crossref","unstructured":"Kaprio E, Prusila R, Tokola S, Kuusisto MEL, Jantunen E, Kuitunen H, et al. Drug\u2010induced pneumonitis risk in diffuse large B\u2010cell\/follicular lymphoma patients treated with R\u2010CHOP\u2010like regimen is associated with the use of granulocyte colony\u2010stimulating growth factors. Cancer Med. 2024;13:e6898.","DOI":"10.1002\/cam4.6898"},{"key":"100594","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/cam4.6898","DOI":"10.1002\/cam4.6898"},{"key":"100595","doi-asserted-by":"crossref","unstructured":"Ekels A, Oerlemans S, Schagen SB, Issa DE, Thielen N, Nijziel MR, et al. The course of self-perceived cognitive functioning among patients with lymphoma and the co-occurrence with fatigue and psychological distress. J Cancer Surviv. 2025;19(1):183\u201396.","DOI":"10.1007\/s11764-023-01458-2"},{"key":"100596","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s11764-023-01458-2","DOI":"10.1007\/s11764-023-01458-2"},{"key":"100597","doi-asserted-by":"crossref","unstructured":"Krolak D, Collins B, Weiss L, Harris C, Van Der Jagt R. Cognitive function and its relationship to other psychosocial factors in lymphoma survivors. Support Care Cancer. 2017;25:905\u201313.","DOI":"10.1007\/s00520-016-3480-z"},{"key":"100598","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00520-016-3480-z","DOI":"10.1007\/s00520-016-3480-z"},{"key":"100599","doi-asserted-by":"crossref","unstructured":"Mariegaard J, Wenstrup J, Lim KZM, Bidstrup PE, Von Heymann A, Johansen C, et al. Prevalence of cognitive impairment and its relation to mental health in Danish lymphoma survivors. Support Care Cancer. 2021;29:3319\u201328.","DOI":"10.1007\/s00520-020-05857-4"},{"key":"100600","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00520-020-05857-4","DOI":"10.1007\/s00520-020-05857-4"},{"key":"100601","doi-asserted-by":"crossref","unstructured":"Baech J, Severinsen MT, \u00d8vlisen AK, Frederiksen H, Vestergaard P, Torp-Pedersen C, et al. Risk of diabetes and the impact on preexisting diabetes in patients with lymphoma treated with steroid-containing immunochemotherapy. Blood Adv. 2022;6:4427\u201335.","DOI":"10.1182\/bloodadvances.2021006859"},{"key":"100602","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006859","DOI":"10.1182\/bloodadvances.2021006859"},{"key":"100603","doi-asserted-by":"crossref","unstructured":"Laugesen K, Ludvigsson JF, Schmidt M, Gissler M, Valdimarsdottir UA, Lunde A, et al. Nordic health registry-based research: a review of health care systems and key registries. CLEP. 2021;13:533\u201354.","DOI":"10.2147\/CLEP.S314959"},{"key":"100604","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/CLEP.S314959","DOI":"10.2147\/CLEP.S314959"},{"key":"100605","unstructured":"Keskimaki I, Tynkkynen L-K, Reissell E, Koivusalo M, Syrja V, Vuorenkoski L, et al. Finland: health system review. Health Syst Transit. 2019;21:1\u2013166."}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/42539\/49286","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/42539\/49286","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T18:02:36Z","timestamp":1756404156000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/42539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":71,"URL":"https:\/\/doi.org\/10.2340\/1651-226x.2025.42539","relation":{},"ISSN":["1651-226X"],"issn-type":[{"value":"1651-226X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]}}}